ReviewBreast cancer research and treatment2019
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Review in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Systematic review and network meta-analysis of the effects of plant active substance on quality of life in breast cancer patients.Frontiers in pharmacology · 2025Pooled it
- Brazilian Cardio-oncology Guideline - 2020.Arquivos brasileiros de cardiologia · 2020Guideline
- QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.British journal of cancer · 2024Trial
- Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial.Medical oncology (Northwood, London, England) · 2024Trial
- The gut-heart axis in cardio-oncology.Cardiovascular research · 2026Review
- Article
- CARDIOVASCULAR COMPLICATIONS OF CHEMOTHERAPY IN BREAST CANCER: A SCOPING REVIEW.Annals of Ibadan postgraduate medicine · 2026Article
- Biological and Teratogenic Evaluations of Nitrogen Heterocycles for Anticancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- 'Patients are left not knowing': Trastuzumab (Herceptin) cardiac risk information and management in HER2-positive breast cancer-a qualitative study of patient experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Investigating Time-Varying Predictor Effects on Cardiovascular Outcomes in Breast Cancer Survivors.Journal of breast cancer · 2026Article
- A Cohort Study on Cardiovascular Disease Mortality in Breast Cancer Patients With Different Subtypes.The breast journal · 2026Article
- An Updated Comprehensive Pharmacovigilance Study of Drug- Induced Breast Cancer Based on FDA Adverse Event Reporting System Data.Current medicinal chemistry · 2026Article
- Mechanistic study of antisense long non-coding RNAExploration of targeted anti-tumor therapy · 2026Article
- Multilevel classification framework for breast cancer cell selection and its integration with advanced disease models.iScience · 2025Review
- Inetetamab triggers cardiotoxicity through its interaction with apoptosis, oxidative stress and autophagy pathways.Scientific reports · 2025Article
- Article
- Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer.iScience · 2025Review
- Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center.Cureus · 2025Article
- Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains over the past decades. However, improved survival has resulted in an increased need for management and mitigation of adverse events associated with anticancer therapy. Cardiac adverse events such as decreased ejection fraction and heart failure have been of particular concern in patients with HER2+ breast cancer. Anti-HER2 agents and chemotherapies (specifically anthracyclines, which are frequently used to treat HER2+ disease) have been associated with cardiotoxicity. As increasing numbers of patients are living longer due to more effective therapy, a better understanding of both monitoring and management of cardiotoxicity is urgently needed.
methodsA comprehensive review of the literature was conducted via PubMed in January 2018 for phase II and phase III trials of "trastuzumab", "lapatinib", "pertuzumab", "T-DM1", "neratinib", in "breast cancer". Literature was evaluated for content related to cardiac adverse events.
findingsWe describe the incidence of and proposed mechanisms for the cardiotoxicity of available HER2-targeted therapies. We summarize current and emerging practices in the management of cardiotoxicity and provide guidance for routine patient care in real-world practice using illustrative patient scenarios.
conclusionsThe future of cardiotoxicity management in patients with HER2+ breast cancer is discussed, with a focus on novel techniques to improve cardiac outcomes, including new imaging modalities, biomarkers, interventional therapies, and ongoing trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.